Antipodean will complete a focused programme of product development in 2011.

1. Complete the phase 2b clinical study of MitoQ tablets in liver disease.

Our goal is to develop the first drug to normalize elevated plasma liver enzyme (ALT and AST) levels. We plan to position MitoQ as a new drug to normalize liver function as measured by plasma ALT levels and thus prevent diabetes and liver damage leading to cirrhosis, transplant or hepatocellular carcinoma. Patients with elevated plasma ALT levels due to fatty liver disease have a 30% chance of proceeding to fibrosis (NASH) in 5 years.

Patients with NASH will become diabetic and have a 40% chance of dying from a liver related illness (cirrhosis or carcinoma). Prevention of this cascade at the early stage of liver inflammation as measured by plasma ALT has the analogy with statins, the world’s leading pharmaceutical selling products that reduce elevated plasma cholesterol levels and thus reduce the risk of cardiovascular related death. In UK, statins are advised for anyone believed to have a 20% chance of developing heart disease in the next 10 years.

To achieve this we need confirmatory data from our phase 2b clinical trial. This study completed all regulatory and ethical approvals in UK  and is now recruiting patients at 4 UK sites under the direction of the eminent expert on liver disease, Professor Chris Day, Newcastle.

2. Outlicense Mitoquinol 0.5% topical cream and 1% topical serum for cosmetic dermatology to a global marketing corporation.

Mitoquinol 0.5% cream and 1.0% serum are ready to launch consumer products.

Antipodean has developed a topical formulation/s of the patented compound, Mitoquinol. Our research collaboration with Dr John Voorhees at the University of Michigan, Department of Dermatology, has identified this compound as a potent inhibitor of photo oxidative damage to human skin keratinocytes and fibroblasts. Dermatological indications being targeted include wrinkling,  photoaging and
infrared IR-A sunblock.